Table 2.
Proportion of Patients Vaccinated against Influenza, Pneumococcus, and Herpes Zoster Vaccines Before and After the 12-Month Intervention Period
| Pre-Intervention (%) | Post-Intervention (%) | |
|---|---|---|
| Influenza (N=102, 101)* | ||
| Ever received influenza vaccine | 92 (90.2) | 87 (86.1) |
| Received influenza vaccine in previous season | 81 (79.4) | 79 (78.2) |
| Pneumococcal (N=1255)† | ||
| Ever received any type of vaccine | 360 (28.7) | 575 (45.8) |
| PPSV 23 only | 351 (28.0) | 293 (23.3) |
| PCV 13 only | 5 (0.4) | 151 (12.0) |
| PPSV 23 and PCV 13 | 4 (0.3) | 131 (10.4) |
| No vaccine received, medical reason | 0 | 9 (0.7) |
| No vaccine received, patient reason | 2 (0.2) | 51 (4.1) |
| Herpes Zoster (N=1255)† | ||
| Ever received vaccine | 32 (2.5) | 57 (4.5) |
| Prescription to receive elsewhere, no record of receipt | 0 | 28 (2.2) |
| No vaccine received, medical reason | 0 | 102 (8.1) |
| No vaccine received, patient reason | 0 | 46 (3.7) |
*
Rates of influenza vaccination are based on self-report from a random sample of 102 patients who were interviewed for the study prior to implementation of the intervention and 101 who were interviewed after implementation of the intervention.
†
Rates of pneumococcal and herpes zoster vaccination are based on electronic health record data for all eligible patients
PPSV 23 – Pneumococcal Polysaccharide Vaccine; PCV 13 - Pneumococcal Polysaccharide Vaccine; HZV – Herpes Zoster Vaccine